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Abstract
Oral contraceptive (OC) use is associated with increased intra-renal renin-angiotensin-aldosterone
system (RAA System) activity and risk of nephropathy, though the contribution of progestins
contained in the OC in the regulation of angiotensin-dependent control of the renal circulation has
not been elucidated. Eighteen OC users (8 non-diabetic, 10 Type 1 diabetic) were studied in high
salt balance, a state of maximal RAA System suppression. Progestational and androgenic activity
of the progestin in each OC was standardized to that of the reference progestin norethindrone.
Renal plasma flow (RPF) was measured by paraaminohippurate clearance at baseline and in
response to angiotensin converting enzyme (ACE)-inhibition. There was a positive correlation
between OC progestational activity and the RPF response to ACE-inhibition (r=0.52, p=0.03).
Similar results were noted with OC androgenic activity (r=0.54, p=0.02). On subgroup analysis,
only non-diabetic subjects showed an association between progestational activity and angiotensin-
dependent control of the renal circulation (r=0.71, p=0.05 non-diabetic; r=0.14, p=0.7 diabetic;
p=0.07 between groups). Similar results were noted with respect to androgenic activity (r=0.88,
p=0.005 non-diabetic; r=−0.33, p=0.3 diabetic; p=0.002 between groups). Our results suggest that
the OC progestin component is a significant influence on the degree of angiotensin-dependent
control of the renal circulation, though these findings may not apply to women with diabetes.
Keywords
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Introduction
Oral contraceptive (OC) use has been associated with increased intrarenal rennin-
angiotensin-aldoesterone system (RAA System) activity1–3 and risk of nephropathy,4–6
though the relative individual contributions of the progestin and estrogen components in the
OC have not been elucidated. While most OCs contain ethinyl estradiol as the synthetic
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testrogen component, they contain different progestins which vary in terms of their chemical
composition, potency and formulary dose. As a result, synthetic progestins have varying
levels of progestational and androgenic activity,7 and these sex hormones have each been
shown to affect RAA System activity.8–10
The importance of the type of progestin contained in hormonal preparations has been
previously highlighted.11, 12 Studies have suggested a link between adverse cardiac,13
vascular,14 and thrombotic15 events depending on the type of progestin exposure, and that
the type of progestin in a hormonal preparation may play a role in attenuating the vascular
effects of estrogen.11, 16 A recent study suggests that OCs containing some newer
generation progestins are associated with worsening blood pressure, urinary albumin
excretion and renal function;17 though the exact mechanism remains unclear, animal studies
have shown an inverse association between exogenous progestin administration and the
pressor response to Ang II,18, 19 suggesting a relationship between progestins and activity
of the RAA System. While it is clear that ingestion of OCs is associated with an altered state
of intrarenal RAA System activity in both non-diabetic2, 3, 6 and diabetic6 women, the
influence of the OC progestin component on the degree of angiotensin-dependent control of
the renal circulation in humans is not known. Furthermore, as we have previously shown
that OC use further enhances the RAA System activation that occurs in diabetes,6 we sought
to determine whether the progestin component in the OC influences the response to ACE-
inhibition in not only healthy subjects, but also in women with diabetes.
Given the link between progestins and altered RAA System activity, and the strong
association between increased renal RAA System activity and OC use, we hypothesized that
the level of progestational and androgenic activity of the progestin in the OC was a
determinant of the degree of angiotensin-dependent control of the renal circulation in
humans. Thus, we examined renal hemodynamic function, both at baseline and in response
to the angiotensin converting enzyme (ACE)-inhibitor captopril in 18 women stratified
according to diabetic status, as a function of OC progestational and androgenic activity.
Materials and Methods
Subjects
Eighteen female OC users (8 non-diabetic, 10 Type 1 diabetes) participated in the study.
Subjects completed an initial medical history, physical examination, electrocardiogram, and
laboratory screening. No subject was taking medication other than OCs and insulin. Subjects
were questioned as to the specific OC they were ingesting, from which the dosage of ethinyl
estradiol and the type and amount of progestin was derived. If the OC was a multiphasic
formulation, an average daily concentration was derived unless the exact dosage at the time
of the study was known. The progestational and androgenic activity of each progestin was
expressed as receptor binding affinity (RBA) and standardized to the activity of the
progestin norethindrone, as has been done previously in human studies.20 All subjects gave
written informed consent. The study protocol was approved by the local Institutional Review
Board.
Protocol
Subjects consumed >200mmol sodium/day for 4 days before the study. Sodium, creatinine,
and protein excretion were measured from a 24h urine collection; no data were excluded
because of dietary noncompliance. Subjects were studied in the supine position after an 8h
fast. At 8:00 A.M., an intravenous catheter was placed in each arm(for infusion and blood
sampling). Fasting plasma glucose concentrations were measured at the start of the study.
Diabetic subjects received intravenous insulin at 0.015units/kg/h, titrated to maintain blood
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tglucose between 80–150mg/dl (4.4–8.3mmol/L). Blood pressure (BP) was recorded every
15min by an automatic recording device (Dinamap; Critikon, Tampa, FL). A loading dose of
8mg/kg of para-aminohippurate (PAH), followed by a constant infusion of PAH at 12mg/
min was given for 90min to establish baseline renal hemodynamic measurements, followed
by 25mg captopril taken orally. PAH clearance and plasma renin activity were measured at
baseline and up to 240min after captopril ingestion.
Analytical methods
Renal clearance was assessed with PAH (Clinalfa, Läufelfingen, Switzerland) as previously
described.21 Serum PAH was measured by an autoanalyzer. Plasma renin activity (PRA)
was assayed by radioimmunoassay.21
Statistical analysis
The primary analysis tested associations between OC progestational and androgenic activity
and change in RPF in response to ACE-inhibition. Study subject baseline and response to
captopril measures were compared using nonparametric methods. The chi-square test was
used to compare frequencies. Renal vascular resistance (RVR) was calculated using the
equation RVR = [(mean arterial BP–12) ×723 / RPF]. Statistical analyses were performed
using Stata (version 9.0; Stata, College Station, TX) with two-tailed significance levels of
0.05.
Results
Baseline characteristics
All subjects were normotensive and none were obese (Table 1). There were no significant
differences in baseline characteristics between non-diabetic and diabetic subjects. The OCs
ingested by all subjects contained progestins structurally related to testosterone. No subjects
were ingesting OCs containing progesterone-derived progestins (Table 2).
Renal and System ic hemodynamic responses to captopril
As anticipated, all subjects demonstrated a renal vasodilatory response to ACE-inhibition
(p=0.0005), which did not differ by diabetic status (p=0.6)(Table 3). While no association
was observed between the dose of ethinyl estradiol and the RPF response to captopril (r=
−0.14, p=0.6), there was a positive correlation between increasing OC progestational
activity and the RPF response to ACE-inhibition (r=0.52, p=0.03)(Figure 1). Similar results
were noted with increasing OC androgenic activity (r=0.54, p=0.02)(Figure 2). A
multiplicative effect of increased progestational and androgenic activity on the RPF
response to ACE-inhibition was observed (p=0.01). On sub-group analysis, only non-
diabetic subjects showed an association between increasing progestational activity of the
progestin component of the OC and angiotensin-dependent control of the renal circulation
(r=0.71, p=0.05 for non-diabetic subjects; r=0.14, p=0.7 for diabetic subjects; p=0.07 for
difference between groups). Similar results were noted with respect to androgenic activity of
the OC progestin component (r=0.88, p=0.005 for non-diabetic subjects, r=−0.33, p=0.3 for
diabetic subjects; p=0.002 for difference between groups) (Figure 3).
Mean arterial pressure decreased in response to ACE-inhibition in all subjects, (p=0.004),
and the decrease in MAP was similar between non-diabetic and diabetic subjects (p=0.2).
Neither OC progestational nor androgenic activity influenced the MAP response to captopril
(p=0.5 for OC progestational activity, p=0.4 for OC androgenic activity). There was no
correlation between the change in MAP and the change in RPF in response to ACE-
inhibition (p=0.1).
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tRenal vascular resistance (RVR) decreased significantly in all subjects with ACE-inhibition
(p=0.003 for all subjects, p=0.03 for non-diabetic subjects, p=0.005 for diabetic subjects). A
negative correlation was noted between change in RVR and both progestational activity (r=
−0.49, p=0.04 all subjects; r=−0.58, p=0.1 non-diabetic subjects; r=−0.67, p=0.03 diabetic
subjects), and androgenic activity (r=−0.49, p=0.04 all subjects; r=−0.53, p=0.2 non-diabetic
subjects; r=−0.57, p=0.08 diabetic subjects). The enhanced renovascular response to
captopril in OC users with higher progestational or androgenic activity was not reflected in
the PRA, thus suggesting a difference in local tissue RAA System activity, such as in the
kidney.
Discussion
In this study of 18 women ingesting OCs while in high salt balance, a state of maximal RAA
System suppression, a positive correlation between increasing OC progestational activity
and RPF response to ACE-inhibition was observed. Similarly, greater OC androgenic
activity was also positively associated with the RPF response to captopril, suggesting that
increasing progestational and androgenic activity in the OC is associated with enhanced
angiotensin-dependent control of the renal circulation, and thus a potential increase in the
risk of nephropathy.
Many factors are associated with RAA System activation. Diabetes22, 23 and acute
hyperglycemia are both linked to an activated renal RAA System in healthy24, 25 and
diabetic subjects,26 though all of our subjects were euglycemic. Nephron loss ultimately
results in increased Ang II production,27 but all subjects had baseline renal hemodynamics
in the normal range. A positive correlation between body mass index and the renal response
to ACE-inhibition has been shown,28 but all subjects were non-obese. While smoking is
hypothesized to lead to increased Ang II production,29 premenopausal women appear to be
least affected by the adverse renal effects of smoking.29
Progestin composition and thereby its inherent progestational and androgenic activity vary
widely amongst the different OC formulations and thus it may not be possible to completely
separate the progestational and androgenic effects of a particular progestin. Furthermore, the
evaluation of progestational and androgenic activity of the OC progestin in humans is
challenging, but can include measuring the progestin affinity for and binding to the
progesterone (PR) and androgen receptor (AR), its effect on sex hormone binding globulin
and free testosterone levels, and its degree of binding to sex hormone binding globulin.30–
33 However, all progestins bind to the progestin receptor34 and exert the majority of their
biological effects through their interactions with specific PRs.35 Testosterone-derived
progestins also bind to the AR.34 Both PRs36 and ARs37, 38 have been identified in the
kidney, suggesting that it is a target organ for these sex hormones and evaluation of RBA is
a suitable method of determining the progestational and androgenic activity of the OC
progestin. While this is the first study using progestational and androgenic RBA as a means
of evaluating the effects of the OC progestin on renal hemodynamics, other investigators
have used a similar method in human studies.20
Animal studies support a positive relationship between progesterone levels and RAA System
activity,18, 19, 39, 40 though few studies exist in humans. In postmenopausal women,
addition of progesterone to estrogen therapy was associated with an increase in circulating
components of the RAA System.41 In the low-salt state, increased endogenous serum
progesterone concentrations in hypertensive, postmenopausal women are associated with a
blunting of the BP and RVR response to infused Ang II, though these effects were abolished
in high-salt balance.10 It is thus conceivable that the lack of association between
progestational activity and change in PRA in our study is due to the fact that all of our
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tsubjects were in the high-salt state. However, caution must be used in directly applying
these findings regarding endogenous progesterone to synthetic progestin as there are clear
structural and functional differences between the two compounds.42
Androgens also stimulate synthesis and activity of the RAA System.43–45 In rats, PRA is
positively correlated to testosterone levels8, 46, 47 and androgen levels predict angiotensin-
dependent control of arterial BP.48 Men demonstrate higher PRA levels compared to
women,49, 50 and a sexual dimorphism has been noted in renal RAS activity.51, 52
Androgens play a crucial role in mediating renal injury and hypertension not only in men,
but also in women in a physiological state of high androgen levels, such as menopause.53
We are unaware of previous studies looking at the androgenic content of OCs and its effects
at the level of the kidney, and one could hypothesize from the results of our study that
increased RAA System activity associated with chronic exposure to high androgenic activity
from the OC may be detrimental to renal function.
This study has limitations. First, we did not show an association between ethinyl estradiol
content and activation of the RAA System in our study as has been previously shown, 2, 3,
6, 54, 55 which may be a reflection of lack of power due to limited sample size and narrow
range of ethinyl estradiol in the studied OC formulations. Second, the study sample was not
from a target patient population in that participants were selected for normal BP, renal
function, and urinalysis. By studying a homogeneous sample with stable ethinyl estradiol
exposure, we hoped to examine the impact of the progestin component of the OC, without
confounding factors. Third, while we included subjects with Type 1 diabetes, we controlled
glycemic status throughout the study and exclusion of diabetic subjects did not alter the
results. Previous studies have suggested that OC use has similar renal effects in both non-
diabetic and diabetic OC users.3, 4, 6, 17 Fourth, we have used RPF response to captopril as
a surrogate marker of renal RAA System activity in our study. While indirect, this approach
is one of the few methods available for determining intrarenal RAA System in humans. The
RPF response to ACE inhibition is highly correlated with angiotensin receptor blockade in
both healthy56 and diabetic57 subjects. The lack of correlation between changes in BP or
PRA and the RPF in response to captopril makes it extremely probable that the RPF
response to ACE-inhibition reflects reversal of an increase in Ang II–mediated renal
vascular tone. Fifth, while there are limited data on the pharmacokinetics of most progestins,
58 considerably more is known about testosterone-derived progestins (as used by all study
subjects) with the majority of data obtained from studies in which the progestin was a
component of an OC formulation.58 Finally, while similar to that of other human studies
examining the hemodynamic effects of the OC2, 3, 59–61, our sample size was limited,
though this effect was minimized by ensuring all subjects were ingesting similar amounts of
salt to minimize RAA System activation.
In our study, women ingesting OCs with higher progestational and androgenic activity
demonstrated increased angiotensin-dependent control of the renal circulation, suggesting a
role for OC progestins as a determinant of renal RAA System activity. While larger,
confirmatory studies are needed prior to recommending changes to clinical practice, the
findings of this study merit attention given the strong association between RAA System
activity and nephropathy.
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tFigure 1. RPF response to ACE-inhibition as a function of progestational activity
R = 0.52, P = 0.03, N = 18
Abbreviations: RPF, renal plasma flow; ACE, angiotensin converting enzyme; RBA,
receptor binding affinity
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tFigure 2. RPF response to ACE-inhibition as a function of androgenic activity
R = 0.54, P = 0.02, N = 18
Abbreviations: RPF, renal plasma flow; ACE, angiotensin converting enzyme; RBA,
receptor binding affinity
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tFigure 3. Renal plasma flow response to ACE-inhibition as a function of progestational and
androgenic activity of the OC progestin, by diabetic status
▲ Progestational Activity
△ Androgenic Activity
— Progestational Activity
--- Androgenic Activity
Non-Diabetics:
Progestational Activity: R=0.71, p=0.05; Androgenic Activity: R=0.88, p=0.005
Diabetics:
Progestational Activity: R=0.14, p=0.7; Androgenic Activity: R= −0.33, p=0.3
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Table 1
Baseline Characteristics*
All Subjects Non-Diabetic Diabetic
(n=18) (n=8) (n=10)
Age (years) 23±4 23±3 23±5
Smoker n (%) 3 (17) 1 (13) 2 (20)
BMI (kg/m2) 25±4 25±6 25±3
MAP (mmHg)† 83±6 84±5 83±6
Duration of Diabetes (years) - - 9.8±4.1
Hemoglobin A1c (%) - - 7.6±1.7
Ethinyl estradiol (µg/tablet) 32±5 33±3 31±6
Progestin (mg/tablet) 0.43±0.42 0.54±0.49 0.34±0.35
    Progestational Activity (RBA) 0.71±0.52 0.79±0.59 0.64±0.48
    Androgenic Activity (RBA) 0.75±0.56 0.75±0.67 0.74±0.48
PRA (ng Ang I/mL/h) 0.5±0.45 0.5±0.36 0.6±0.53
Fasting Serum Glucose (mg/dL) (mmol/L) 122±67 (6.8±3.7) 80±5 (4.4±0.3) 151±78 (8.4±4.3)
Urine Sodium (mmol/24h) 276±89 282±83 272±98
RPF (ml/min/1.73m2)† 614±73 646±81 588±57
RVR (mmHg/mL/min/1.73m2) 85±11 81±11 88±10
Abbreviations: BMI, body mass index; MAP, mean arterial pressure; PRA, plasma rennin activity; Ang I, angiotensin I; RPF, renal plasma flow
*
Data are expressed as mean ± standard deviation unless otherwise indicated
†
Median of readings at t = −10 min, −5 min and 0
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Table 2
Progestin component of oral contraceptive, by subject
Non-Diabetic Subjects Diabetic Subjects
Progestin Type Dose Progestin Type Dose
Desogestrel* 0.15 mg Desogestrel* 0.15 mg
Norethindrone* 0.75 mg Ethynodiol diacetate* 1 mg
Norethindrone* 1.5 mg Levonorgestrel* 0.1 mg
Norethindrone acetate* 1 mg Levonorgestrel* 0.1 mg
Norgestimate* 0.215 mg Norethindrone* 1 mg
Norgestimate* 0.215 mg Norgestimate* 0.18 mg
Norgestimate* 0.25 mg Norgestimate* 0.215 mg
Norgestimate* 0.25 mg Norgestimate* 0.215 mg
Norgestimate* 0.215 mg
Norgestimate* 0.25 mg
*
Structurally related to testosterone
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Table 3
Response to angiotensin-converting enzyme inhibition*
All Subjects Non-Diabetic Diabetic
(n=18) (n=8) (n=10)
MAP Nadir (mmHg)† 78±7§ 81±6§ 76±7§
ΔMAP (mmHg) −5±7 −3±5 −7±8
Peak PRA (ng Ang I/mL/h) 1.9±2.4§ 2.6±3.4§ 1.5±1.3§
ΔPRA (ng Ang I/mL/h) 1.4±2.2 2.1±3.1 0.9±1.0
Peak RPF (ml/min/1.73m2)‡ 699±123§ 733±152§ 672±94§
ΔRPF (ml/min/1.73m2) 85±85 87±122 84±44
Nadir RVR (mmHg/mL/min/1.73m2) 70±11§ 70±16§ 69±11§
ΔRVR (mmHg/mL/min/1.73m2) −15±9 −11±9 −18±7
Abbreviations: MAP, mean arterial pressure; PRA, plasma renin activity; Ang I, angiotensin I; RPF, renal plasma flow.
*
Data are expressed as mean ± standard deviation unless otherwise indicated
†
Mean of 2 readings at nadir of response to captopril
‡
Mean of 2 readings at peak response to captopril
§
p<0.05 compared to baseline
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Table 4
Summary Table
What is known
about topic
• Oral contraceptive use is associated with increased intrarenal RAS activity and risk of nephropathy
• Progestins in the oral contraceptive have been associated with increased blood pressure, albuminuria and loss of kidney
function by an unclear mechanism
• The role of progestins in the oral contraceptive in activation of the RAA System is unknown
What this study
adds
• Progestational activity of the oral contraceptive predicts degree of intrarenal RAA System activity
• Androgenic activity of the oral contraceptive predicts degree of intrarenal RAA System activity
• Given the strong association between RAA System activity and kidney disease, women at risk of nephropathy may wish
to consider oral contraceptives with low progestational and androgenic activity
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